Sirtratumab vedotin
Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker[1].
Product Specifications
CAS Number
[1824663-83-3]
Product Name Alternative
AGS15E; ASG-15ME; 1vcMMAE
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs)
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
96.42
Solubility
H2O
Smiles
[Sirtratumabvedotin]
References & Citations
[1]Morrison K, et al. Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker. Mol Cancer Ther. 2016 Jun;15 (6) :1301-10.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99595/Sirtratumab-vedotin-SDS-MedChemExpress.pdf
Scientific Category
ADC Related
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Mouse Monoclonal GM-CSFR alpha Antibody (31916) [Janelia Fluor 635]](https://cdn.genprice.uk/genprice/genprice5.png)
FAB706JF635 0.5 mL
Mouse Monoclonal GM-CSFR alpha Antibody (31916) [Janelia Fluor 635]
Ask
View Details 
MBS6473318-01 0.1 mL
DYRK2, NT (Dual-specificity Tyrosine-phosphorylation Regulated Kinase 2) (MaxLight 750)
Ask
View Details MBS6473318-02 5x 0.1 mL
DYRK2, NT (Dual-specificity Tyrosine-phosphorylation Regulated Kinase 2) (MaxLight 750)
Ask
View Details